Literature DB >> 22301626

Role of cyclooxygenase-1-mediated prostacyclin synthesis in endothelium-dependent vasoconstrictor activity of porcine interlobular renal arteries.

Bin Liu1, Wenhong Luo, Yingzhan Zhang, Hui Li, Ningxia Zhu, Dongyang Huang, Yingbi Zhou.   

Abstract

This study aimed to determine whether PGI(2) would be evoked by the endogenous endothelial B(2) receptor agonist bradykinin (BK) in the porcine interlobular renal artery and, if so, to determine how it would influence the vasomotor reaction, and the specific cyclooxygenase (COX) isoform(s) involved in its synthesis. The production of the PGI(2) metabolite 6-keto-PGF(1α) was analyzed with HPLC-mass spectroscopy, while vasomotor reaction to PGI(2) or BK was determined with isometric force measurement. Results showed that BK evoked an increase in the production of 6-keto-PGF(1α), which was abolished by endothelial denudation that removed COX-1 expression, or was reduced by COX-1 inhibition. Interestingly, PGI(2) evoked a potent contraction, which was prevented by antagonizing thromboxane-prostanoid (TP) receptors and was not enhanced by antagonizing the vasodilator PGI(2) (IP) receptors. The IP receptor agonists MRE-269 and iloprost did not induce any relaxation. Moreover, iloprost, which is also a PGI(2) analog, caused a contraction, which was sensitive to TP receptor antagonism, but was to a significantly lesser extent than that of PGI(2). Indeed, IP receptors were not detected by RT-PCR or Western blotting in the vessel. Following nitric oxide synthase (NOS) inhibition, BK also evoked an endothelium-dependent contraction, which was blocked by TP receptor antagonism. In addition, inhibition of COX-1 (but not COX-2) impeded the vasoconstrictor activity of BK and expedited the relaxation induced by the agonist in NOS-intact vessels. These results demonstrate that in the porcine interlobular renal artery BK evokes endothelial COX-1-mediated PGI(2) synthesis, which mainly leads to the activation of TP receptors and a vasoconstrictor response, possibly due to a scarcity of vasodilator activity mediated by IP receptors. Also, our data suggested that the effect of a PGI(2) analog on TP receptors could be reduced compared with that of PGI(2) due to modified structure as with iloprost.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22301626     DOI: 10.1152/ajprenal.00604.2011

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  5 in total

1.  Role of E-type prostaglandin receptor EP3 in the vasoconstrictor activity evoked by prostacyclin in thromboxane-prostanoid receptor deficient mice.

Authors:  Zhenhua Li; Yingzhan Zhang; Bin Liu; Wenhong Luo; Hui Li; Yingbi Zhou
Journal:  Sci Rep       Date:  2017-02-06       Impact factor: 4.379

2.  Increased role of E prostanoid receptor-3 in prostacyclin-evoked contractile activity of spontaneously hypertensive rat mesenteric resistance arteries.

Authors:  Bin Liu; Mengyi Zhan; Yingzhan Zhang; Hui Li; Xiangzhong Wu; Fengfeng Zhuang; Wenhong Luo; Yingbi Zhou
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

3.  EP3 Blockade Adds to the Effect of TP Deficiency in Alleviating Endothelial Dysfunction in Atherosclerotic Mouse Aortas.

Authors:  Chuangjia Hu; Bin Liu; Yineng Xu; Xiangzhong Wu; Tingting Guo; Yingzhan Zhang; Jing Leng; Jiahui Ge; Gang Yu; Jinwei Guo; Yingbi Zhou
Journal:  Front Physiol       Date:  2019-09-26       Impact factor: 4.566

4.  Endothelial cyclooxygenase-1 paradoxically drives local vasoconstriction and atherogenesis despite underpinning prostacyclin generation.

Authors:  Jane A Mitchell; Fisnik Shala; Maria Elisa Lopes Pires; Rachel Y Loy; Andrew Ravendren; Joshua Benson; Paula Urquhart; Anna Nicolaou; Harvey R Herschman; Nicholas S Kirkby
Journal:  Sci Adv       Date:  2021-03-19       Impact factor: 14.136

5.  Vasomotor Reaction to Cyclooxygenase-1-Mediated Prostacyclin Synthesis in Carotid Arteries from Two-Kidney-One-Clip Hypertensive Mice.

Authors:  Bin Liu; Zhenhua Li; Yingzhan Zhang; Wenhong Luo; Jiling Zhang; Hui Li; Yingbi Zhou
Journal:  PLoS One       Date:  2015-08-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.